# EDGAR Filing Document

**Accession Number:** 0001806310
**File Stem:** 0001193125-26-253478
**Filing Date:** 2026-6
**Character Count:** 7518
**Document Hash:** 2c85e0c97816a6a62db41ab142b288cc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-253478.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001193125-26-253478

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260601

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Taysha Gene Therapies, Inc.
- **CENTRAL INDEX KEY:** 0001806310
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843199512
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39536
- **FILM NUMBER:** 261055898

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 PEGASUS PARK DRIVE
- **STREET 2:** SUITE 1430
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75247
- **BUSINESS PHONE:** (214) 612-0000

**MAIL ADDRESS:**
- **STREET 1:** 3000 PEGASUS PARK DRIVE
- **STREET 2:** SUITE 1430
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75247

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): June 1, 2026

## Taysha Gene Therapies, Inc.

#### (Exact name of registrant as specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39536** | **84-3199512** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **3000 Pegasus Park Drive, Suite 1430**<br> **Dallas, Texas** | **75247** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

(214) 612-0000

#### (Registrant's Telephone Number, Including Area Code)

#### Not Applicable

#### (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.00001 par value | TSHA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 1, 2026, Taysha Gene Therapies, Inc. (the "**Company**") held its 2026 annual meeting of stockholders (the "**Annual Meeting**"). At the Annual Meeting, the stockholders considered four proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2026 (the "**Proxy Statement**"). Of the 287,341,999 shares outstanding as of the record date, 243,857,812 shares, or approximately 84.86%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

**Proposal No. 1**: Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes For** | **Votes Withheld** | **Votes Withheld** |
|  Sean P. Nolan |  | 169142295 |  | 35742331 |
|  Laura Sepp-Lorenzino, Ph.D. |  | 150094517 |  | 54790109 |

---

Broker Non-Votes: 38,973,186

Both nominees were elected.

**Proposal No. 2**: Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstained** | **Abstained** |
|  Ratification of selection of Deloitte & Touche LLP |  | 243814085 |  | 25551 |  | 18176 |

---

Broker Non-Votes: 0

**Proposal No. 3**: Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. The votes were cast as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Votes For** | **Votes For** | **Votes Against** | **Votes Against** | **Abstained** | **Abstained** |
|  Approval of the compensation of the Company's named executive officers |  | 168142551 |  | 36396784 |  | 345291 |

---

Broker Non-Votes: 38,973,186

**Proposal No. 4**: Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers. The votes were cast as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **One Year** | **One Year** | **Two<br>Years** | **Two<br>Years** | **Three<br>Years** | **Three<br>Years** | **Abstained** | **Abstained** |
|  Advisory indication of preferred frequency of future shareholder advisory votes on Company's named executive officer compensation |  | 203825717 |  | 360924 |  | 630378 |  | 67607 |

---

Broker Non-Votes: 38,973,186

Consistent with the stockholder voting results above and the recommendation of the board of directors of the Company (the "**Board***"*) as disclosed in the Proxy Statement for the Annual Meeting, the Company has determined to solicit a non-binding advisory vote on the compensation of the Company's named executive officers every year until the next required stockholder vote on the frequency of such non-binding advisory vote, or until the Board of the Company determines that a different frequency of such non-binding advisory vote is in the best interest of the Company's stockholders.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Taysha Gene Therapies, Inc.** | **Taysha Gene Therapies, Inc.** |
| Dated: June 2, 2026 | By: | /s/ Kamran Alam |
|  |  | Kamran Alam |
|  |  | Chief Financial Officer |

---